DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, has signed an agreement with Kyowa Hakko Kirin (Thailand) Co. Ltd., to provide regulatory consulting and product registration services for new biotechnology drugs in Thailand.

“We decided to outsource the registration of our products in Thailand to DKSH due to their strong technical expertise, their solid track record in product registration and their dedication to quality,” said Makoto Ikeda, managing director, Kyowa Hakko Kirin (Thailand) Co. Ltd.

“We are proud to provide Market Expansion Services to Kyowa Hakko Kirin in Thailand. Their decision to outsource regulatory services to DKSH underlines our position as the partner of choice for healthcare companies who want to efficiently register their products in Thailand,” commented Sumalee Nathikanjanalab, Client Business Director

The agreement between DKSH and Kyowa Hakko Kirin underlines DKSH’s ability to provide full-service solutions to its clients and will further strengthen DKSH’s market position in the region while contributing incrementally to the Group’s overall earnings and profitability over time.

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on oncology, nephrology and immunology/allergy. The company leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world.

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.